Skip to content
drillr.ai
Sign up

ABEO

Abeona Therapeutics Inc.

NASDAQ · Healthcare · Biotechnology · US

$6.00
+1.18%
Ask drillr

  • Aug 13, 2026, 14:05 UTC

    Abeona Therapeutics reported second-quarter revenue growth from its ZEVASKYN cell therapy launch, while noting operational challenges in patient scheduling and manufacturing that affected revenue recognition.

    Source:

  • Jul 21, 2026, 11:30 UTC

    Abeona Therapeutics Inc. activated Cincinnati Children's as the seventh Qualified Treatment Center for ZEVASKYN.

    Source:

  • Jun 12, 2026, 00:00 UTC

    Michael Amoroso resigned from the Board of Directors of Abeona Therapeutics Inc., effective June 11, 2026.